aaiPharma Inc., of Wilmington, N.C., named Philip Tabbiner president and chief operating officer and named David Hurley president of NeoSan Pharmaceuticals.

Cambrex Corp., of East Rutherford, N.J., appointed Peter Tombros to its board.

Celgene Corp., of Warren, N.J., appointed Jayne Butler director of new product planning and Sean Maenpaa product director of Thalomid, and promoted Amy Cavers to executive director of marketing.

Chugai Biopharmaceuticals Inc., of San Diego, appointed Miguel Barbosa vice president of discovery biology.

Cypress Bioscience Inc., of San Diego, appointed Sabrina Martucci Johnson interim chief financial officer.

Genelabs Technologies Inc., of Redwood City, Calif., promoted Kenneth Schwartz to vice president of medical affairs.

Genencor International Inc., of Palo Alto, Calif., named Mark Goldsmith vice president, molecular medicine and strategy, and Kim Graham vice president, drug development.

Genteric Inc., of Alameda, Calif., appointed David Karlin vice president of clinical development.

Incyte Genomics Inc., of Palo Alto, Calif., appointed Brian Metcalf executive vice president and chief drug discovery scientist.

Institute of Forest Biotechnology, of Research Triangle Park, N.C., named Edward Makowski executive director.

Microbia Inc., of Cambridge, Mass., added Richard Bailey as senior director, biomanufacturing business development.

Myogen Inc., of Denver, appointed Michael Gerber senior vice president of clinical development and regulatory affairs.

Nanogen Inc., of San Diego, added Ira Marks as vice president of business development and said Randy Berholtz will assume the role of acting general counsel and secretary.

Ontogen Corp., of Carlsbad, Calif., appointed Steven Cowell to its board.

Surface Logix Inc., of Boston, appointed Chi-Chi Zhu vice president of business development, Paul Sweetnam chief scientific officer and Greg Kirk vice president of technology.

VaxGen Inc., of Brisbane, Calif., appointed James Panek senior vice president of manufacturing operations.